首页> 外文期刊>Nature >Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
【24h】

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

机译:广泛中和的HIV-1抗体与Founder病毒共同进化

获取原文
获取原文并翻译 | 示例
       

摘要

Current human immunodeficiency virus-1 (HIV-1) vaccines elicit strain-specific neutralizing antibodies. However, cross-reactive neutralizing antibodies arise in approximately 20% of HIV-1-infected individuals, and details of their generation could provide a blueprint for effective vaccination. Here we report the isolation, evolution and structure of a broadly neutralizing antibody from an African donor followed from the time of infection. The mature antibody, CH103, neutralized approximately 55% of HIV-1 isolates, and its co-crystal structure with the HIV-1 envelope protein gpl20 revealed a new loop-based mechanism of CD4-binding-site recognition. Virus and antibody gene sequencing revealed concomitant virus evolution and antibody maturation. Notably, the unmutated common ancestor of the CH103 lineage avidly bound the transmitted/founder HIV-1 envelope glycoprotein, and evolution of antibody neutralization breadth was preceded by extensive viral diversification in and near the CH103 epitope. These data determine the viral and antibody evolution leading to induction of a lineage of HIV-1 broadly neutralizing antibodies, and provide insights into strategies to elicit similar antibodies by vaccination.
机译:当前的人类免疫缺陷病毒1(HIV-1)疫苗会引起菌株特异性中和抗体。但是,交叉反应中和抗体出现在大约20%感染HIV-1的个体中,其生成细节可以为有效疫苗接种提供蓝图。在这里,我们报告了从感染之日起从非洲捐助者那里分离的,广泛中和的抗体的结构,进化和结构。成熟的抗体CH103中和了大约55%的HIV-1分离株,其与HIV-1包膜蛋白gp120的共晶体结构揭示了一种基于环的CD4结合位点识别机制。病毒和抗体基因测序揭示了伴随的病毒进化和抗体成熟。值得注意的是,CH103谱系的未突变共同祖先狂热地结合了已传播/建立的HIV-1包膜糖蛋白,并且在CH103表位及其附近进行了广泛的病毒多样化之前,抗体中和宽度的演变。这些数据确定了导致广泛中和抗体的HIV-1谱系诱导的病毒和抗体进化,并提供了通过疫苗接种引发相似抗体的策略的见识。

著录项

  • 来源
    《Nature》 |2013年第7446期|469-476c3|共9页
  • 作者单位

    Duke University Human Vaccine Institute, Departments of Medicine and Immunology, Duke University School of Medicine, Durham, North Carolina 27710, USA,Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, Durham, North Carolina 27710, USA;

    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA;

    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA;

    Duke University Human Vaccine Institute, Departments of Medicine and Immunology, Duke University School of Medicine, Durham, North Carolina 27710, USA,Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, Durham, North Carolina 27710, USA;

    Duke University Human Vaccine Institute, Departments of Medicine and Immunology, Duke University School of Medicine, Durham, North Carolina 27710, USA,Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery, Durham, North Carolina 27710, USA;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 02:53:34

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号